T-Cell Immunotherapy Market Size, Share, Opportunities, And Trends By Type (Chimeric antigen receptor, T-cell receptor, Tumor-infiltrating lymphocyte), By Indication (Melanoma, Leukemia, Ovarian cancer, Others), And Geography - Forecasts From 2025 To 2030

T-Cell Immunotherapy Market Size:

T-Cell Immunotherapy Market is projected to reach USD 10.723 billion by 2030 from USD 6.277 billion in 2025, with a 11.30% CAGR.

T-Cell immunotherapy changes body immune cells, as in this the T-cell of the person is taken out and are changed genetically during the process and then the changed cells are grown in large numbers and are injected into the patient’s body so that they can fight cancer cells naturally. This CAR T-cell immunotherapy is a promising cancer treatment for patients and also due to the rising prevalence of cancer and lack of ideal biomarkers for early detection of cancer this therapy is considered as the driving factor for the growth of the market. According to World Health Organization cancer is responsible for an estimated 9.6 million deaths in 2018 and nearly 70% of the deaths from cancer occur in low and middle-income countries, so this therapy can help the patient fight the cancer cells without much trouble and due to the rapidly increasing research and development activities and technological advancements in cancer treatment the T-cell immunotherapy market is likely to increase. The future of the immunotherapy involves the personalized approach where the sample of the tumor will be taken and then after doing the research the personalized T-cells will be created for the particular person. However, side effects like CRS, neurologic problems and health issues associated with CAR T-Cell therapy is considered as the restraining factor for the growth of the market.

T-Cell Immunotherapy Market Drivers:

• Reliable and effective treatment with minimum side effects
• Growing occurrence of cancer in both adults and children

T-Cell Immunotherapy Market Restraints:

• Neurological and CRS problems which occur during treatment.
• High cost

The major players profiled in the T-Cell Immunotherapy market include Cellular Biomedicine Group, Autolus Novartis, Gilead Sciences, Inc., Adaptimmune Therapeutics, Cellectis, Bluebird bio, Immunocore, Innovative Cellular Therapeutics, Iovance Biotherapeutics, Celgene

Segmentation

The T cell Immunotherapy market has been analyzed through the following segments:

• By Type
  • Chimeric antigen receptor (CAR)
  • T-cell receptor (TCR)
  • Tumor-infiltrating lymphocyte (TIL)
• By Indication
  • Melanoma
  • Leukemia
  • Ovarian cancer
  • Others
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • Others
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Currency

1.5. Assumptions

1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation

4.2. Market Drivers

4.3. Market Restraints

4.4. Market Opportunities

4.5. Porter’s Five Force Analysis

4.5.1. Bargaining Power of Suppliers

4.5.2. Bargaining Power of Buyers

4.5.3. Threat of New Entrants

4.5.4. Threat of Substitutes

4.5.5. Competitive Rivalry in the Industry

4.6. Life Cycle Analysis - Regional Snapshot

4.7. Market Attractiveness

5. T- CELL IMMUNOTHERAPY MARKET BY TYPE.

5.1. Chemeric antigen receptor (CAR) T-cell

5.2. T-cell receptor (TCR)

5.3. Tumor-infiltrating lymphocyte (TIL)

6. T-CELL IMMUNOTHERAPY MARKET BY INDICATION

6.1. Melanoma

6.2. Leukemia

6.3. Ovarian cancer

6.4. Others

7. T-CELL IMMUNOTHERAPY MARKET BY GEOGRAPHY

7.1. North America

7.1.1. USA

7.1.2. Canada

7.1.3. Mexico

7.2. South America

7.2.1. Brazil

7.2.2. Argentina

7.2.3. Others

7.3. Europe

7.3.1. Germany

7.3.2. France

7.3.3. United Kingdom

7.3.4. Spain

7.3.5. Others

7.4. Middle East and Africa

7.4.1. Saudi Arabia

7.4.2. Israel

7.4.3. Others

7.5. Asia Pacific

7.5.1. China

7.5.2. Japan

7.5.3. South Korea

7.5.4. India

7.5.5. Others

8. COMPETITIVE INTELLIGENCE

8.1. Company Benchmarking and Analysis

8.2. Recent Investment and Deals

8.3. Strategies of Key Players

9. COMPANY PROFILES

9.1. Cellular Biomedicine Group

9.2. Autolus Novartis

9.3. Gilead Sciences, Inc.

9.4. Adaptimmune Therapeutics

9.5. Cellectis

9.6. Bluebird bio

9.7. Immunocore

9.8. Innovative Cellular Therapeutics

9.9. Iovance Biotherapeutics

9.10. Celgene

LIST OF FIGURES

LIST OF TABLES

Cellular Biomedicine Group

Autolus Novartis

Gilead Sciences, Inc.

Adaptimmune Therapeutics

Cellectis

Bluebird bio

Immunocore

Innovative Cellular Therapeutics

Iovance Biotherapeutics

Celgene